ProQR Therapeutics N.V.
PRQR
$1.63
$0.095.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 190.22% | 356.93% | 366.22% | 243.79% | 84.56% |
| Total Other Revenue | 701.62% | -6.89% | -40.26% | -62.93% | -89.13% |
| Total Revenue | 196.41% | 312.62% | 302.58% | 187.72% | 54.60% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 196.41% | 312.62% | 302.58% | 187.72% | 54.60% |
| SG&A Expenses | -15.84% | 1.55% | -9.00% | -8.30% | -10.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.92% | 15.00% | -15.85% | -24.95% | -38.98% |
| Operating Income | 12.33% | 20.55% | 41.59% | 39.12% | 45.26% |
| Income Before Tax | -0.63% | 30.52% | 57.87% | 52.53% | 55.24% |
| Income Tax Expenses | -149.71% | -128.79% | -1,155.46% | -189.87% | -186.02% |
| Earnings from Continuing Operations | -0.21% | 30.90% | 58.35% | 52.73% | 55.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 100.00% | -181.79% | -2.24% | -78.72% |
| Net Income | 1.17% | 31.65% | 57.86% | 52.44% | 54.97% |
| EBIT | 12.33% | 20.55% | 41.59% | 39.12% | 45.26% |
| EBITDA | 14.18% | 22.53% | 43.97% | 40.93% | 46.72% |
| EPS Basic | 7.73% | 34.87% | 61.38% | 57.27% | 60.21% |
| Normalized Basic EPS | 21.26% | 33.21% | 50.81% | 48.11% | 51.18% |
| EPS Diluted | 7.83% | 34.88% | 61.62% | 57.28% | 60.32% |
| Normalized Diluted EPS | 21.26% | 33.21% | 50.81% | 48.11% | 51.18% |
| Average Basic Shares Outstanding | 6.27% | 3.44% | 6.47% | 9.67% | 13.08% |
| Average Diluted Shares Outstanding | 6.27% | 3.44% | 6.47% | 9.67% | 13.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |